https://www.selleckchem.com/products/azd9291.html
4%, Hodgkin lymphoma 5.0% and other 11.9%. Causes of death were disease progression/relapse (65.2%), second malignancy (17.0%), infection (9.8%) and other (8.0%). Non-relapse mortality was 1.2% (95% confidence interval 0.4-3. and 3.2% (1.7-5.7) at 100 days and 1 year, respectively, post-HSCT. Overall survival at 2 years was 81.0% (73.8-86.4) for MM and 69.6% (58.8-78.1) for non-Hodgkin lymphoma. The median progression-free survival in the MM cohort was 3.3 years. CONCLUSION The Townsville Hospital transplant centre provides an importa
Like
Comment
Share
